HZNP News and Press, Horizon Therapeutics Public Limited Company From 08/03/22

Horizon Therapeutics Public Limited Company (HZNP) Q2 2022 Results Earnings Conference Call August 3, 2022, 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive O...

Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...

Horizon Therapeutics ( NASDAQ: HZNP ) is trading 22% lower before the bell after the company posted lower-than-expected Q2 results and full-year sales guidance that were below estimates, hurt by lower sales from its inflammation segment. The company said the launch...

Hydrofarm Holdings Group HYFM -27% on slashed guidance amid hydroponics recession . Meihua International Medical Technologies ( MHUA ) -13% . MDJM ( MDJH ) -21% . Match Group MTCH -21% on Q2 earnings release . Horizon Therapeutics Public...

The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2022 Q2 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2022 Q2 - Results - Earnings Call Presentation

Horizon Therapeutics press release ( NASDAQ: HZNP ): Q2 Non-GAAP EPS of $1.07 misses by $0.26 . Revenue of $876.4M (+5.3% Y/Y) misses by $62.42M . Revises Full-Year 2022 Guidance : Full-Year 2022 Net Sales guidance of $3.53 Billion to $3.60 Billion vs....

Second-Quarter 2022 Results: -- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million -- -- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million -- -- TEPEZZA ® (teprotumumab-trbw) Net Sales of $479.8 Mi...

Horizon Therapeutics ( NASDAQ: HZNP ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $1.33 (-17.9% Y/Y) and the consensus Revenue Estimate is $936.16M (+12.5% Y/Y). Over the last 2 years, HZNP ...

Horizon Therapeutics roared past the $100 per share mark in mid-2021 as I predicted it would do in a 2020 note for SA. The company's share price has dipped in 2022, however, and with Q2 '22 earnings days away, there is a chance for investors to capitalise. Horizon is forecasting f...

My portfolio, built specifically for my retirement ~20+ years from now, benefits from a surprise Petrobras gift. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retirement egg. A po...